Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OCUP $3.75 -FDA Decision in September followed by Phase results for another indication . Market cap $79 m - Cash $39 m enough untill mid 2025 potential milestone payment of $10 million upon FDA approval not included . The Drug is already partnered with Viatris (VTRS) . A very cheap FDA play here ...
OCUP $3.75 -FDA Decision in September followed by Phase results for another indication . Market cap $79 m - Cash $39 m enough untill mid 2025 potential milestone payment of $10 million upon FDA approval not included . The Drug is already partnered with Viatris (VTRS) . A very cheap FDA play here ...
DERM $1.70 - Phase 3 data next week if positive this cheap low floater could double fast ...
"Topline data from the DFD-29 Phase 3 clinical studies are expected to be announced in June of 2023."
DERM $1.85 -Phase 3 results IMMINENT should come this or next week ..this low floater could run to $5 on positive outcome
"Topline data from the DFD-29 Phase 3 clinical studies are expected to be announced in June of 2023."
DERM $1.85 -Phase 3 results IMMINENT should come this or next week ..this low floater could run to $5 on positive outcome
$1.65 -Phase 3 results within days if positive this low floater could double or triple quickly
company has many marketed drugs and trading at cash ...DFD-29 will be the game changer for the company if successful in phase 3 , it has best in class potential in rosacea and the treatment could reach $100+ million in annual sales .
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023
Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29
(DERM) up 20% -P3 results within days (expected during June) if positive this low floater could double or more . company shas low valuation of 30 million while cash is at $26 million .
(DERM) $1.50 -Ph 3 results in June , company has many marketed drugs and trading at cash ...DFD-29 will be the game changer for the company if successful in phase 3 , it has best in class potential in rosacea and the treatment could reach $100+ million in annual sales .
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023
Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29
(DERM) $1.50 -Ph 3 results in June , company has many marketed drugs and trading at cash ...DFD-29 will be the game changer for the company if successful in phase 3 , it has best in class potential in rosacea and the treatment could reach $100+ million in annual sales .
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023
Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29
(KOD) $9 up over 100% in last 3 weeks and still trading just at cash level and about to report 3x Phase 3 results in July and another one in September . This stock could run to $13-15 ahead of the readouts ...
(ATHA) $2.98 - Alzheimer P2/3 data in Q1 and stock trading at huge discount of 50% under cash balance makes it the cheapest Alzheimer stock on Nasadaq
(DERM) $1.20 -Ph 3 results in June , company has many marketed drugs and trading at cash ...DFD-29 will be the game changer for the company if successful in phase 3 , it has best in class potential in rosacea and the treatment could reach $100+ million in annual sales .
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023
Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29
(DERM) $1.20 -Ph 3 results in June , company has many marketed drugs and trading at cash ...DFD-29 will be the game changer for the company if successful in phase 3 , it has best in class potential in rosacea and the treatment could reach $100+ million in annual sales .
Achieved “Last Patient Out” milestone in Phase 3 clinical program evaluating DFD-29 in May 2023
Topline data are expected in June 2023 for Phase 3 clinical program evaluating DFD-29
(KOD) $6.90 -4x Phase 3 results in July and September plus stock trading way below cash balance ..Baker Bros who holding 33% of the company paid more than $50 per share for many of their shares . Cash per Share alone is $8.09
"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly"
Baker Bros Ownership
http://openinsider.com/screener?s=KOD&o=&pl=&ph=&ll=&lh=&fd=730&fdr=&td=0&tdr=&fdlyl=&fdlyh=&daysago=&xp=1&vl=&vh=&ocl=&och=&sic1=-1&sicl=100&sich=9999&istenpercent=1&grp=0&nfl=&nfh=&nil=&nih=&nol=&noh=&v2l=&v2h=&oc2l=&oc2h=&sortcol=0&cnt=100&page=1
(KOD) $6.90 -4x Phase 3 results in July and September plus stock trading way below cash balance ..Baker Bros who holding 33% of the company paid more than $50 per share for many of their shares . Cash per Share alone is $8.09
"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly"
Baker Bros Ownership
http://openinsider.com/screener?s=KOD&o=&pl=&ph=&ll=&lh=&fd=730&fdr=&td=0&tdr=&fdlyl=&fdlyh=&daysago=&xp=1&vl=&vh=&ocl=&och=&sic1=-1&sicl=100&sich=9999&istenpercent=1&grp=0&nfl=&nfh=&nil=&nih=&nol=&noh=&v2l=&v2h=&oc2l=&oc2h=&sortcol=0&cnt=100&page=1
ATHA $2.90- Alzheimer P2/3 data in Q1 ..stock trading 50% under cash balance
"The company expects topline data from its Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimer’s disease in early 2024.
An independent data monitoring committee recommended continuing the study in patients with mild-to-moderate Alzheimer’s in October after an unblinded interim efficacy and futility analysis."
KOD up 11% lot of Phase 3 readouts imminent starting in July and stock still trading under cash
(KOD) $5.60 - 4x Ph 3 readouts in July plus stock trading way below cash balance ..Baker Bros who holding 33% of the company paid more than $50 per share for many of their shares (link below)
"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly"
Baker Bros Ownership
http://openinsider.com/screener?s=KOD&o=&pl=&ph=&ll=&lh=&fd=730&fdr=&td=0&tdr=&fdlyl=&fdlyh=&daysago=&xp=1&vl=&vh=&ocl=&och=&sic1=-1&sicl=100&sich=9999&istenpercent=1&grp=0&nfl=&nfh=&nil=&nih=&nol=&noh=&v2l=&v2h=&oc2l=&oc2h=&sortcol=0&cnt=100&page=1
4x Phase 3 results in July plus stock trading way below cash balance ..Baker Bros who holding 33% of the company paid more than $50 per share for most of their shares (link below)
"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly"
Baker Bros Ownership
http://openinsider.com/screener?s=KOD&o=&pl=&ph=&ll=&lh=&fd=730&fdr=&td=0&tdr=&fdlyl=&fdlyh=&daysago=&xp=1&vl=&vh=&ocl=&och=&sic1=-1&sicl=100&sich=9999&istenpercent=1&grp=0&nfl=&nfh=&nil=&nih=&nol=&noh=&v2l=&v2h=&oc2l=&oc2h=&sortcol=0&cnt=100&page=1
(KOD) $5.60 - 4x Phase 3 results in July plus stock trading way below cash balance ..Baker Bros who holding 33% of the company paid more than $50 per share for most of their shares (link below)
"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly"
Baker Bros Ownership
http://openinsider.com/screener?s=KOD&o=&pl=&ph=&ll=&lh=&fd=730&fdr=&td=0&tdr=&fdlyl=&fdlyh=&daysago=&xp=1&vl=&vh=&ocl=&och=&sic1=-1&sicl=100&sich=9999&istenpercent=1&grp=0&nfl=&nfh=&nil=&nih=&nol=&noh=&v2l=&v2h=&oc2l=&oc2h=&sortcol=0&cnt=100&page=1
(KOD) $5.60 - 4x Phase 3 results in July plus stock trading way below cash balance ..Baker Bros who holding 33% of the company paid more than $50 per share for most of their shares (link below)
"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly"
Baker Bros Ownership
http://openinsider.com/screener?s=KOD&o=&pl=&ph=&ll=&lh=&fd=730&fdr=&td=0&tdr=&fdlyl=&fdlyh=&daysago=&xp=1&vl=&vh=&ocl=&och=&sic1=-1&sicl=100&sich=9999&istenpercent=1&grp=0&nfl=&nfh=&nil=&nih=&nol=&noh=&v2l=&v2h=&oc2l=&oc2h=&sortcol=0&cnt=100&page=1
(KOD) $5.60 --4x Phase 3 results in Q3 plus stock trading way below cash balance ..Baker Bros who holding 33% of the company paid more than $50 per share for most of their shares .
"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly"
Baker Bros Ownership
http://openinsider.com/screener?s=KOD&o=&pl=&ph=&ll=&lh=&fd=730&fdr=&td=0&tdr=&fdlyl=&fdlyh=&daysago=&xp=1&vl=&vh=&ocl=&och=&sic1=-1&sicl=100&sich=9999&istenpercent=1&grp=0&nfl=&nfh=&nil=&nih=&nol=&noh=&v2l=&v2h=&oc2l=&oc2h=&sortcol=0&cnt=100&page=1
(KOD) $5.60 --4x Phase 3 results in Q3 plus stock trading way below cash balance ..Baker Bros who holding 33% of the company paid more than $50 per share for most of their shares .
"We are on the cusp of four Phase 3 study readouts in major indications, starting with results of our GLEAM, GLIMMER and DAYLIGHT studies expected in July and our GLOW study in September. Following our successful pivotal study readout in retinal vein occlusion last year, we look forward to unmasking the primary endpoint data in these next four studies shortly"
Baker Bros Ownership
http://openinsider.com/screener?s=KOD&o=&pl=&ph=&ll=&lh=&fd=730&fdr=&td=0&tdr=&fdlyl=&fdlyh=&daysago=&xp=1&vl=&vh=&ocl=&och=&sic1=-1&sicl=100&sich=9999&istenpercent=1&grp=0&nfl=&nfh=&nil=&nih=&nol=&noh=&v2l=&v2h=&oc2l=&oc2h=&sortcol=0&cnt=100&page=1
LPCN completed 17:1 RS today ahead of the upcoming data readouts expected during this quarter
LPCN 0.33 up 23% ...data readout from their postpartum depression trial expected during this quarter followed by results from the liver cirrhosis trial
(LPCN) $0.26-- Postpartum depression and Liver Cirrhosis Phase 2 readout in Q2 , stock trading under cash balance . this stock could be a 10 bagger if we get positive results
presentation
file:///C:/Users/Rosen/Downloads/Corporate%20Deck%205-5-2023-2.pdf
(LPCN) $0.25-- Postpartum depression and Liver Cirrhosis Phase 2 readout in Q2 , stock trading under cash balance . this stock could be a 10 bagger if we get positive results
presentation
file:///C:/Users/Rosen/Downloads/Corporate%20Deck%205-5-2023-2.pdf
(LPCN) $0.24 -- Depression and Liver Cirrhosis P2 data readout expected during this quarter
(TCON) $0.70 - Sarcoma final interim data in Q3 - BLA filing expected in 2024 ..Massive insider buying above $1.20+ see link below .. Positive data could push this stock toward $5
Report the second and final interim efficacy analysis from the ENVASARC pivotal trial following the review of more than 12 weeks of efficacy data (including two on-study CT scans) by the independent data monitoring committee from 46 patients who receive envafolimab as a single agent and 46 patients who receive envafolimab in combination with Yervoy®, which we expect in the third quarter of 2023.
Insider buying
http://openinsider.com/search?q=tcon
(EQRX) $1.70 - 2 Cancer drugs awaiting approval in Europe with potential first approval in 2H of this year / Market cap $845 m trading massive below the cash balance of $1.4 billion ...Alphabet (Google) , Softbank , Blackrock and Vanguard alone holding over 100 million shares who paid around $10 per share ...
Aumolertinib: MAAs accepted for review by MHRA and EMA for EGFR-mutated NSCLC
Sugemalimab: MAAs accepted for review by MHRA and EMA for the first-line treatment of metastatic NSCLC in combination with chemotherapy
Ended 2022 with $1.4 billion in cash, cash equivalents and short-term investments; anticipate runway into 2028
Top Shareholders
https://www.cnbc.com/quotes/eqrx?tab=ownership
EQRX $1.82 trading massive under cash + 2 cancer drugs awaiting approval expected in Q3 or Q4
(EQRX) $1.70 - 2 Cancer drugs awaiting approval in Europe with potential first approval in 2H of this year / Market cap $845 m trading massive below the cash balance of $1.4 billion ...Alphabet (Google) , Softbank , Blackrock and Vanguard alone holding over 100 million shares who paid around $10 per share ...
Aumolertinib: MAAs accepted for review by MHRA and EMA for EGFR-mutated NSCLC
Sugemalimab: MAAs accepted for review by MHRA and EMA for the first-line treatment of metastatic NSCLC in combination with chemotherapy
Ended 2022 with $1.4 billion in cash, cash equivalents and short-term investments; anticipate runway into 2028
Top Shareholders
https://www.cnbc.com/quotes/eqrx?tab=ownership
--
DERM is a under radar gem and most shares held by insiders